Exicure Inc XCUR:NASDAQ

Last Price$2.22NASDAQ Closing Price as of 4:00PM ET 1/26/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.07(3.06%)
Bid (Size)$2.21 (3)
Ask (Size)$2.26 (20)
Day Low / High$2.20 - 2.33
Volume582.3 K
  • Latest Stories
  • Commentary and Analysis
Exicure Secures Two Fast Track Designations for Cavrotolimod From FDA; Stock Climbs
10:34AM ET 1/11/2021 MT Newswires

Exicure (XCUR) said on Monday the US Food and Drug Administration has granted Fast Track designations for its product candidate, cavrotolimod, for the...

Exicure Files for Up to $150 Million Mixed Shelf
3:23AM ET 12/22/2020 MT Newswires

Exicure (XCUR) on Monday filed a registration statement covering the potential sale of up to $150 million in securities. The securities, which may be...

Exicure Obtains Two US Patents, Patent Allowance for Mechanics Behind Anti-Tumor Agent Cavrotolimod
11:27AM ET 12/21/2020 MT Newswires

Exicure (XCUR) said Monday that it has received two US patents as well as patent allowance covering cavrotolimod, which is being developed as a potential...

--Analyst Actions: BMO Capital Starts Exicure at Outperform With $6 Price Target
8:29AM ET 12/18/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (XCUR) EXICURE Reports Q3 Revenue $2.4M
7:13AM ET 11/12/2020 MT Newswires

...

--Analyst Actions: Chardan Capital Adjusts Price Target on Exicure to $7 From $5, Maintains Buy Rating
7:36AM ET 9/17/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Exicure's Cavrotolimod Demonstrates Therapeutic Activity in Early-Stage Solid Tumor Trial
10:34AM ET 9/16/2020 MT Newswires

Exicure (XCUR) said Wednesday that results from an ongoing clinical trial of a combination of drugs to treat solid tumors had triggered a response in about...

-- Earnings Flash (XCUR) EXICURE INC. Reports Q2 Revenue $4.847M
7:00AM ET 8/12/2020 MT Newswires

...

Exicure Joins Russell 2000 Index
7:21AM ET 6/29/2020 MT Newswires

Biotech company Exicure Inc. (XCUR) said Monday it has been added to the Russell 2000 Index, effective last Friday. Price: 2.7500, Change: +0.07, Percent...

Exicure Treats First Patient in Dose Expansion Stage of Trial of Cancer Drug Cavrotolimod
7:51AM ET 6/16/2020 MT Newswires

Exicure (XCUR), a US biotechnology firm, said early Tuesday it has begun dosing the first patient in the dose expansion stage of the phase 1b/2 clinical...